Focus on Standardisation, Quality by Design and Regulatory GMP - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Focus on Standardisation, Quality by Design and Regulatory GMP
June and July saw three major US conferences on implementing single-use technologies: the IBC Single-use Applications meeting, the PDA Single-use Workshop and the Bio-Process Systems Alliance (BPSA) International Single-use Summit (ISUS). Jerold Martin highlights some of the key topics discussed at these meetings.


Pharmaceutical Technology Europe
Volume 23, Issue 11

Regulatory GMP focus explained at BPSA conference

The third important single-use conference of the summer was the BPSA International Single-Use Summit, which was held in Washington, DC on 27–29 July. This inaugural conference for BPSA served as a forum for suppliers and users to highlight the business model for single-use. In addition to business leader speakers, the summit featured J. David Doleski, the consumer safety officer at FDA Center for Drug Evaluation and Research. Doleski opened with a review of relevant FDA regulations that impact single-use manufacturing, including 21 CFR 211.65 on Equipment, 211.94 on Drug Containers, 600.3 on Biological Purity and 600.11 on Biological Control. Each of these has similar statements about assuring that process equipment and containers do not adversely affect the drug or biological product. Additional compendial standards noted were USP General Chapters <87> and <88> on Biological Reactivity, <661> on Plastics and <381> on Elastomers, as well as relevant FDA guidances, including cGMP for Phase I Investigational Drugs (July 2008) and Container Closure Systems for Packaging Human Drugs and Biologics (May 1999).

Advantages of single-use manufacturing were recognised as:

  • Reduced need for cleaning and sterilisation systems and validation
  • Reduced risk of crosscontamination
  • Improved containment
  • Potentially greater control over aseptic operations (as facilitated with sterile connectors/disconnectors and tube welders/sealers).

Doleski's talk included an excellent overview of topics that should be incorporated in process documentation and FDA filings. Initially highlighted were considerations for vendor partnerships and materials control, included establishment of manufacturing quality agreements, vendor audits, notifications of changes in product (i.e., materials or design), certificates of analyses, and flow path testing for endotoxin, particulates and bioburden (where necessary). With regards to sanitisation (e.g., irradiation for microbial control) or sterilisation, bioprocessers should note where sterilisation is performed (i.e., contract irradiator) and provide documentation on the sterilisation validation method, sterilisation records, impact on materials (supplier validation data) and repeated sterilisation where applied (note that single-use systems are generally not suitable for multiple irradiations at doses >25 kGy).

Extractables and leachables studies are performed to assess the potential impact of leachables on product quality, efficacy and safety. This can begin with compatibility and extractables data from the supplier, testing with additional model solvents under manufacturing process parameters (e.g., temperature, pH, pressure and time) where needed, considering the cumulative effect of all manufacturing equipment and conducting further risk assessments to determine if a leachable study is necessary (e.g., for final product formulation).

Process validation considerations should take into account the full range of the manufacturing process, and incorporate multiple unit operations and actual manufacturing parameters, such as mixing speed and duration of perfusion culture. Sterile media simulations should be conducted for filling of sterile product (i.e., bulk or unit dosage). When fluids are stored in single-use containers, validation should include the length of time and temperature range, with assessments of the impact of fluid on materials, and the impact of materials on product, buffers or media and container integrity (leakage) after storage. Where bulk fluids are shipped, considerations should include the effect of pressure changes, such as altitude, effect of motion (i.e., acceleration or vibration) and the protection offered by external containers. Other environmental considerations can include light, chemicals and other mechanical forces that may impact the contained fluid.

Despite commonly cited concerns, leak integrity issues with today's improved biocontainer designs are rare. However, possible issues should be qualified and noted, such as movement or shipping of storage containers, operator error (i.e., handling training), improper operation parameters (i.e., tube welding) and exposure to extreme temperature.

Doleski summarised his talk by saying that the FDA recognises the importance of the user's relationship with their single-use equipment suppliers and expects users to work with suppliers to develop knowledge of their single use equipment, understand their product and processes, consider potential issues, conduct a corresponding risk assessment, perform appropriate validation and establish proper quality systems to maintain a state of control.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology Europe,
Click here